Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The EXAMINE trial showed non-inferiority of the DPP-4 inhibitor alogliptin to placebo on major adverse cardiac event (MACE) rates in patients with type 2 diabetes and recent acute coronary syndromes. Concerns about excessive rates of in-hospital heart failure in another DPP-4 inhibitor trial have been reported. We therefore assessed hospital admission for heart failure in the EXAMINE trial.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet

Title: Lancet (London, England)

ISSN (Electronic): 1474-547X

ISSN (Print): 0140-6736

Publication date (Electronic): May 23 2015

Volume: 385

Issue: 9982

Affiliations

[1 ] Institut Lorrain du Coeur et des Vaisseaux, Centre d'Investigation Clinique Inserm, Université de Lorraine and CHU, Vandoeuvre-Les-Nancy, France. Electronic address: f.zannad@chu-nancy.fr.

[2 ] Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

[3 ] University of Tennessee College of Medicine, Memphis Veterans Affairs Medical Center, Memphis, TN, USA.

[4 ] University of Chicago Pritzker School of Medicine, Chicago, IL, USA.

[5 ] Cleveland Clinic Foundation, Cleveland, OH, USA.

[6 ] Takeda Development Center Americas, Deerfield, IL, USA.

[7 ] Harvard School of Public Health, Boston, MA, USA.

[8 ] Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT, USA.

Article

Publisher Item ID: S0140-6736(14)62225-X

DOI: 10.1016/S0140-6736(14)62225-X

PubMed ID: 25765696

SO-VID: 55d0e2fe-d340-4327-9e50-f682e89a0012

History

Data availability:

Comments

Comment on this article

scite_

Cited by 218

See all cited by